BioLineRx Ltd.: Form 20-F for the period ended Dec 31, 2020
Filed with the SEC on Feb 23, 2021 and accepted by EDGAR at Feb 23, 2021, 12:00 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 12 months2020-01-01 to 2020-12-31 | −$22.9m | ifrs-full:ProfitLossFromOperatingActivities |
| Net income | 12 months2020-01-01 to 2020-12-31 | −$30.0m | ifrs-full:ProfitLoss |
| Operating cash flow | 12 months2020-01-01 to 2020-12-31 | −$23.2m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Cash and equivalents | At period end2020-12-31 | $16.8m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2020-12-31 | $22.9m | ifrs-full:CurrentAssets |
| Total assets | At period end2020-12-31 | $47.3m | ifrs-full:Assets |
| Current liabilities | At period end2020-12-31 | $10.6m | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2020-12-31 | $25.3m | ifrs-full:Liabilities |
| Shareholders' equity | At period end2020-12-31 | $22.0m | ifrs-full:Equity |
| Shares outstanding | At period end2020-12-31 | 349,169,545 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001178913-21-000741. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.